Area of research
Hematology · Genetics
Research interest
Research interests include Medicine, Internal medicine, Myelofibrosis, Myeloid leukemia, Refractory (planetary science), and Essential thrombocythemia.
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia
Survival following allogeneic transplant in patients with myelofibrosis
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin
Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM‐151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms
Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML
Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes
Phase <scp>II</scp> trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of <scp>SWOG</scp> S0325, an intergroup randomized <scp>PHASE II</scp> trial in newly diagnosed chronic phase chronic myeloid leukaemia